Apr 30, 2012
1) Simultaneous PML-IRIS in MS and 2) Topic of the month: Diagnosis of MCI and AD. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Igor Koralnik about his paper on simultaneous PML-IRIS in an MS patient. Dr. Jennifer Fugate is reading our e-Pearl of the week about traumatic brain injury. In the next part of the podcast Dr. Jeff Burns interviews Dr. John Morris about clinical diagnosis of mild cognitive impairment. Over the upcoming weeks they will discuss a number of topics related to mild cognitive impairment and Alzheimer disease. All participants have disclosures.Dr. Keegan serves as eMedicine Chief Editor and is a consultant for Bionest and Novartis. Dr. Koralnik serves on the editorial board of the Journal of NeuroVirology; served on the scientific advisory boards for Hoffman-La Roche Inc., GlaxoSmithKline and Merck Serono; receives royalties from UpToDate, Inc.; has served as a consultant for Bristol-Myers Squibb, Ono Pharmaceuticals Co. LTD., Merck Serone, Hoffman-La Roche Inc., GlaxoSmithKline, Perseid Therapeutic LLC; Vertex Pharmaceuticals; and Johnson & Johnson; receives research support from NIH; and has received research support from Biogen Idec and the National Multiple Sclerosis Society.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Jeff Burns serves on the editorial board of the Journal of Alzheimer's Disease; has served on a scientific advisory board for the American Academy of Physician Education; has received publishing royalties for Early Diagnosis and Treatment of Mild Cognitive Impairment (Wiley Press, 2008) and Dementia: An Atlas of Investigation and Diagnosis (Clinical Publishing, 2007); serves on the speakers' bureau for Novartis; has served as a consultant for Medacorp Consulting, Johnson County Clinical Trials, and PRA International; receives research support from Elan Corporation, Janssen, Wyeth, Pfizer Inc, Danone, and the Dana Foundation; and has served as an expert witness in legal proceedings regarding competency.Dr. Morris serves on scientific advisory boards for Eisai Inc., Esteve, Janssen Alzheimer Immunotherapy Program, GlaxoSmithKline, Novartis, Otsuka Pharmaceuticals Co., Ltd., and Pfizer Inc; serves on the editorial advisory board of Annals of Neurology; receives royalties from the publications of the books Mild Cognitive Impairment and Early Alzheimer's Disease, Dementia, Handbook of Dementing Illnesses, 2nd edition and for an editorial in Lancet Neurology; and receives research support from Janssen Alzheimer Immunotherapy Program and Pfizer Inc.